Orphazyme A / S
Company registration number 32266355
Orphazyme A / S received today a notification regarding the start of the stabilization period
Copenhagen, Denmark, September 29, 2020 With reference to the announcement of the company no. 55/2020 of September 29, 2020 concerning the pricing of the global offer (the global offer), consisting of an initial public offer of American Depositary Shares (the “ADS”), each of these ADS representing one ordinary share (the Ordinary Shares) of Orphazyme, on the Nasdaq Global Select Market in the United States under the symbol “ORPH” (“the US Offer”), and a concomitant private placement of Ordinary Shares in Europe traded on Nasdaq Copenhagen A / S under the symbol ORPHA (the European Private Placement), Orphazyme A / S (“Orphazyme”) has received a notification regarding the start of the stabilization period from BofA Securities, Inc., which acts as stabilizing manager in the Global Offer for ADSs traded on the Nasdaq Global Select Market in the United States and Orphazyme Ordinary Shares traded on Nasdaq Copenhagen A / S, respectively. Reference is made to the attached notice of BofA Securities, Inc., given on behalf of Orphazyme and its subsidiary, BofA Securities Europe SA.
Orphazyme has been informed that stabilization activities will be carried out according to the principles and procedures defined in accordance with US laws and regulations and the Market Abuse Regulation (Commission Regulation (EU) No 596/2014 of April 16, 2014).
This announcement by the Company does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction where such offer, solicitation or sale would be illegal. before registration or qualification. under the securities laws of those states or jurisdictions.
For more information, please contact
Orphazyme A / S
Anders Vadsholt, CFO +45 28 98 90 55
No announcement or information regarding the proposed initial public offering may be released to the public in jurisdictions where registration or prior approval is required for this purpose. No steps have been taken or will be taken for the offering of shares or ADS in any jurisdiction where such steps would be necessary. The issuance or sale of ADS and the subscription or purchase of ADS are subject to special legal or statutory restrictions in certain jurisdictions. Orphazyme is not responsible if these restrictions are not observed by another person.
About Orphazyme A / S
Orphazyme is an advanced-stage biopharmaceutical company pioneering the response to heat shock proteins for the treatment of neurodegenerative orphan diseases. Orphazyme harnesses heat shock protein amplification (or HSP) to develop and commercialize novel therapies for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including storage disease lysosomal and neuromuscular degenerative diseases. Orphazymes lead candidate Arimoclomol is in clinical development for four orphan diseases: Niemann-Pick disease type C (NPC), amyotrophic lateral sclerosis (ALS), sporadic inclusion body myositis (sIBM) and Gaucher’s disease. Orphazyme is headquartered in Denmark and operates in the United States and Switzerland. Orphazymes shares are listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.
This company announcement may contain certain forward-looking statements. While Orphazyme believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this Company’s announcement regarding future events are subject to (i) change without notice and (ii) independent factors. of the will of Orphazymes. These statements may include, but are not limited to, all statements preceded, followed by or including words such as target, believe, expect, aim, intend, may, anticipate, estimate, plan, project, will , have, probably, should, would, could, and other words and terms with similar meanings or their negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the control of Orphazymes which could cause Orphazymes’ actual results, performance or achievements to differ materially from the expected results, performance or achievements expressed or implied. by these forward-looking statements. Except as required by law, Orphazyme assumes no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
BofA Securities, Inc. (Joshua Plump, phone + 1646-855-6765) and BofA Securities Europe SA, (Andrew Briscoe, +44 (0) 7418 937979) hereby notify that the stabilizers named below may stabilize the offer of the securities indicated below, and thus engage in operations which stabilize, maintain or otherwise affect the price of the following securities. Stabilization activities will be carried out in accordance with US securities laws and regulations and in accordance with the disclosure requirements set out in the European Union Market Abuse Regulation, Commission Regulation (EU) no. 596/2014 of April 16, 2014.
|Transmitter:||Orphazyme A / S|
|Securities:||American Depositary Shares (ADS) each representing one ordinary share (ordinary share) of 1 DKK nominal issued by the issuer; and|
Ordinary shares of the issuer
|Offer size:||3,966,146 ADS and 3,650,000 Ordinary Shares (collectively, the Global Offer)|
|Offer price:||USD 11.00 per ADS and DKK 70.1844 per ordinary share|
|Markets:||The Nasdaq Global Select Market in the United States (with regard to ADS); and|
Nasdaq Copenhagen A / S in Denmark (with respect to ordinary shares)
|Teleprinter:||ORPH (Nasdaq Global Select Market)|
ORPHA (Nasdaq Copenhagen A / S)
|Stabilizers:||BofA Securities, Inc. re ADS on the Nasdaq Global Select Market in the United States|
A Bryant Park
New York, New York 10036
BofA Securities Europe SA regarding ordinary shares on Nasdaq Copenhagen A / S in Denmark
51 La Botie Street,
|The stabilization period should begin on:||September 28, 2020 (ET) / September 29, 2020 (CET)|
|The stabilization period should end no later than:||October 28, 2020 (ET) / October 29, 2020 (CET)|
|Maximum size of the over-allotment installation:||Up to 1,142,421 Ordinary Shares, (which may take the form of ADS) representing 15% of the Global Offer|
|Exercise period:||30 calendar days|
|Conditions for using the overuse option:||Can be exerted by stabilizers|
all or part from time to time only to cover
over-allotments or short positions related to
offer or stabilization transactions
As part of this offer, the stabilization agents may over-allot the securities or carry out transactions with a view to supporting the market price of the securities to a level above that which might otherwise prevail. However, there can be no assurance that stabilization will be undertaken and it can be discontinued at any time.
This announcement is for informational purposes only and does not constitute or form part of, and should not be construed as, an invitation or an offer to subscribe, subscribe or otherwise acquire or dispose of securities of the Company in any jurisdiction. is.
This announcement is made in accordance with the principles and procedures of the Market Abuse Regulation (Commission Regulation (EU) No 596/2014 of April 16, 2014), including delegated regulations, as amended from time to time, and is not intended for distribution. to the public in jurisdictions where prior registration or approval is required. No steps have been taken or will be taken for the public offering of Ordinary Shares or ADSs in any jurisdiction other than the United States. The issue or sale of Ordinary Shares and ADS, as well as the subscription or purchase of Ordinary Shares and ADS, may be subject to special legal or statutory restrictions in applicable jurisdictions. Orphazyme is not responsible if these restrictions are not observed by another person.
The ADS is being offered in the United States, only by way of prospectus, which is or will be filed with the Securities and Exchange Commission. A copy of the prospectus for such an offering may be obtained when available, free of charge, by visiting EDGAR at www.sec.gov. Copies of the prospectus relating to the offering may be obtained, when available, from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at [email protected]; Cowen, c / o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] or by phone at (833) 297-2926; or Guggenheim Securities, Attn .: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by phone at (212) 518-9544, or by email at [email protected]
56-2020 Start of stabilization period
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]